Low Rate of Clinically Evident Extravascular Hemolysis in Patients with Paroxysmal Nocturnal Hemoglobinuria Treated with a Complement C5 Inhibitor: Results from a Large, Multicenter, US Real-World Study

Abstract

Jamile Shammo,1 Ajeet Gajra,2 Yogesh Patel,3 Ioannis Tomazos,3 Jonathan Kish,2 Anita Hill,4 J Rafael Sierra,3 David Araten5 1Rush Hematology, Oncology and Cell Therapy, Rush University Medical Center, Chicago, IL, USA; 2Cardinal Health Inc., Charlotte, NC, USA; 3Alexion, AstraZeneca Rare Disease, Boston, MA, USA; 4Alexion, AstraZeneca Rare Disease, Inc., Leeds, UK; 5Division of Hematology, New York University School of Medicine, New York, NY, USACorrespondence: Jamile Shammo, Email [email protected]: Most patients with paroxysmal nocturnal hemoglobinuria (PNH) treated with a complement protein 5 (C5) inhibitor achieve full control of terminal complement activity and intravascular hemolysis. The minority remains anemic and transfusion dependent despite this control. Etiology for ongoing anemia is multifactorial and includes bone marrow failure, breakthrough hemolysis, extravascular hemolysis (EVH) and nutritional deficiencies.Patients and Methods: To evaluate the potential etiologies of hemoglobin levels < 10 g/dL despite receiving C5 inhibitor therapy, we performed a retrospective US chart review of adult patients with PNH and treated for at least 12 months with eculizumab (n=53), ravulizumab (n=32), or eculizumab followed by ravulizumab (n=15). Clinically evident EVH was defined as at least one transfusion, reticulocyte count ≥ 120× 109/L and hemoglobin level ≤ 9.5 g/dL. Safety data were not collected. Mean treatment duration was 26.5± 17.2 months.Results: Treatment with C5 inhibitors significantly improved hemoglobin, lactate dehydrogenase, and number of transfusions versus baseline. Among the patients with hemoglobin < 10 g/dL during the last 6 months of treatment (n=38), one patient (eculizumab) had clinically evident EVH, and 10 patients had active concomitant bone marrow failure. Bone marrow failure was a major contributor to hemoglobin < 10 g/dL and transfusion dependence; clinically evident EVH was uncommon.Conclusion: A range of hematologic causes need to be considered when evaluating anemia in the presence of treatment with a C5 inhibitor.Keywords: real-world, anemia, intravascular hemolysis, bone marrow failure

Keywords

• real-world
• anemia
• intravascular hemolysis
• bone marrow failure